EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway

被引：0

作者：

Gao, Xuyuan ^{[1
]}

Xu, Hang ^{[2
]}

Ho, James C. M. ^{[3
]}

Chan, Oscar S. H. ^{[4
]}

Xu, Feng ^{[5
]}

Wang, Junwen ^{[6
]}

Lee, Victor H. F. ^{[7
]}

Tin, Vicky P. C. ^{[1
]}

Xiao, Zhijie ^{[1
]}

Wang, Siqi ^{[1
]}

Yam, Judy W. P. ^{[1
]}

Wong, Maria P. ^{[1
]}

机构：

[1] Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China

[2] Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China

[3] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China

[4] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Hong Kong, Peoples R China

[5] Univ British Columbia, St Pauls Hosp, Providence Hlth Care, Vancouver, BC, Canada

[6] Mayo Clin, Scottsdale, AZ USA

[7] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-LB-196

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB-196

引用

页数：2

共 50 条

[1] Overcoming ARID1A mutation-induced osimertinib resistance in EGFR-mutant NSCLC leptomeningeal carcinomatosis
Fukuda, Koji
Takeuchi, Shinji
Arai, Sachiko
Nanjo, Shigeki
Yano, Seiji
CANCER SCIENCE, 2024, 115 : 112 - 112
[2] Nkx2-4 Mutation Confers Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Sarcomatoid Carcinoma
Xia, Lexin
Shao, Yang W.
Xia, Yang
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : E125 - E126
[3] Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas
Pirazzoli, Valentina
Takezawa, Ken
de Stanchina, Elisa
Pao, William
Politi, Katerina
CLINICAL CANCER RESEARCH, 2012, 18 (10)
[4] Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Offin, Michael
Rizvi, Hira
Tenet, Megan
Ni, Andy
Sanchez-Vega, Francisco
Li, Bob T.
Drilon, Alexander
Kris, Mark G.
Rudin, Charles M.
Schultz, Nikolaus
Arcila, Maria E.
Ladanyi, Marc
Riely, Gregory J.
Yu, Helena
Hellmann, Matthew D.
CLINICAL CANCER RESEARCH, 2019, 25 (03) : 1063 - 1069
[5] Acquired Resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-Mutant lung cancer among Hispanics (CLICaP)
Zorrilla, A. Cardona
Arrieta, O.
Rojas, L.
Corrales, L.
Vargas, C.
Carranza, H.
Cuello, M.
Martin, C.
Rosell, R.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S15 - S15
[6] A novel BAD phosphorylation inhibitor combined with EGFR tyrosine kinase inhibitors in EGFR-mutant lung adenocarcinoma treatment
Zhang, X.
Shu, C.
Huang, P.
Pandey, V.
Lobie, P. E.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S62 - S62
[7] Baseline Spatial Heterogeneity of T790M in Tyrosine Kinase Inhibitor Naive EGFR-Mutant Lung Adenocarcinomas
Cabanero, M.
Kuo, J.
Liu, N.
Tsao, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S443 - S443
[8] Whole-exome sequencing reveals tyrosine kinase-resistant mutations in pretreatment EGFR-mutant lung adenocarcinomas
Gao, Xu-yuan
Xu, Hang
Ho, James C. M.
Chan, Oscar S. H.
Xu, Feng
Wang, Junwen
Lee, Victor H. F.
Tin, Vicky P. C.
Xiao, Zhijie
Wang, Siqi
Yam, Judy W. P.
Wong, Maria P.
CANCER RESEARCH, 2017, 77
[9] EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
Chen, Zhi-Yong
Zhong, Wen-Zhao
Zhang, Xu-Chao
Su, Jian
Yang, Xue-Ning
Chen, Zhi-Hong
Yang, Jin-Ji
Zhou, Qing
Yan, Hong-Hong
An, She-Juan
Chen, Hua-Jun
Jiang, Ben-Yuan
Mok, Tony S.
Wu, Yi-Long
ONCOLOGIST, 2012, 17 (07): : 978 - 985
[10] Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor
Luo, Jia
Makhnin, Alex
Tobi, Yosef
Ahn, Linda
Hayes, Sara A.
Iqbal, Afsheen
Ng, Kenneth
Arcila, Maria E.
Riely, Gregory J.
Kris, Mark G.
Yu, Helena A.
JCO PRECISION ONCOLOGY, 2021, 5 : 55 - 64

← 1 2 3 4 5 →